Girinimbine (Girinimbin) is a carbazole alkaloid with a variety of biological effects. Girinimbine can induce apoptosis, and has antitrypanosomal, antiplatelet activity, antibacterial activity, anti-inflammatory, antioxidant and antitumor activities[1][2][3].
Girinimbine (1-400 µM; 24-72 h) decreases the viability of HepG2 cells in 24, 48 and 72 h with IC50 values of 61 µM, 56 µM, and 40 µM respectively. Girinimbine (10-100 µM; 24-48 h) increase of LDH leakage in both concentration- and time-dependent manner in HepG2 cells[1].Girinimbine (56 µM; 24-48 h) treatment results in DNA fragmentation and elevates levels of caspase-3 in HepG2 cells[1].HepG2 cells[1].Girinimbine (56 µM; 12-48 h) treatment also displays a time-dependent accumulation of the Sub-G0/G1 peak (hypodiploid) and caused G0/G1-phase arrest[1].Girinimbine shows a potent antitrypanosomal activitywith an IC50 value of 10.16 µg/mL[3].
Girinimbine (10-100 mg/kg; orally gavage; once) pretreatment helps limit total leukocyte migration, and reduced pro-inflammatory cytokine (IL-1β, TNF-α) levels in the peritoneal fluid[2]. In vivo in zebrafish embryos, Girinimbine (20 μg/mL; 24 hours) shows significant distribution of apoptotic cells in embryos[2].
[1]. Suvitha Syam, et al. The growth suppressing effects of girinimbine on HepG2 involve induction of apoptosis and cell cycle arrest. Molecules. 2011 Aug 23;16(8):7155-70.
[2]. Venoos Iman, et al. Anticancer and anti-inflammatory activities of girinimbine isolated from Murraya koenigii. Drug Des Devel Ther. 2016 Dec 28;11:103-121.
[3]. H O Dyary, et al. Antitrypanosomal and cytotoxic activities of botanical extracts from Murraya koenigii (L.) and Alpinia mutica Roxb. Trop Biomed. 2019 Mar 1;36(1):94-102.